Page 1

EX - 99.1 2 gkos - 20210505xex99d1.htm EX - 99.1 GLAUKOS FOR IMMEDIATE RELEASE Contact : Chris Lewis Sr. Director , Investor Relations , Corporate Strategy & Development ( 949 ) 481-0510 clewis@glaukos.com Glaukos Corporation Announces First Quarter 2021 Financial Results San Clemente , CA - May 5 , 2021 Glaukos Corporation ( NYSE : GKOS ) , an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma , corneal disorders and retinal diseases , today announced financial results for the first quarter ended March 31 , 2021. Key highlights include : • Net sales growth of 23 % to $ 68.0 million in Q1 2021 , compared to $ 55.3 million in Q1 2020 . • Glaucoma net sales of $ 53.7 million and Corneal Health net sales of $ 14.3 million in Q1 2021 . • Gross margin of approximately 76 % and non - GAAP gross margin of approximately 84 % in Q1 2021 . • Operating expenses of $ 63.1 million and non - GAAP operating expenses of $ 61.8 million in Q1 2021 . “ Our strong start to the year reflects our teams ' unwavering commitment to advance our key strategic priorities and execute our plans , ” said Thomas Burns , Glaukos president and chief executive officer . “ While we recognize uncertainties associated with COVID - 19 may persist , I am encouraged by the continued recovery trends and believe our business prospects remain robust as we advance our mission to transform the treatment of chronic eye diseases for the benefit of patients worldwide . " First Quarter 2021 Financial Results Net sales increased 23 % in the first quarter of 2021 to $ 68.0 million , compared to $ 55.3 million in the same period in 2020 . Gross margin for the first quarter of 2021 was approximately 76 % , compared to approximately 41 % in the same period in 2020. Non - GAAP gross margin for the first quarter of 2021 was approximately 84 % , compared to approximately 84 % in the same period in 2020 . Selling , general and administrative ( SG & A ) expenses for the first quarter of 2021 declined 17 % to $ 41.9 million , compared to $ 50.5 million in the same period in 2020. Non - GAAP SG & A expenses for the first quarter of 2021 declined 1 % to $ 40.7 million , compared to $ 41.1 million in the same period in 2020 . Research and development ( R & D ) expenses for the first quarter of 2021 declined 15 % to $ 21.2 million , compared to $ 24.9 million in the same period in 2020. Non - GAAP R & D expenses for the first quarter of 2021 declined 8 % to $ 21.1 million , compared to $ 22.9 million in the same period in 2020 .